{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T00:40:49Z","timestamp":1740184849592,"version":"3.37.3"},"reference-count":59,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T00:00:00Z","timestamp":1726444800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020955","name":"GlaxoSmithKline Biologicals SA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020955","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jaci-global.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology: Global"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.jacig.2024.100343","type":"journal-article","created":{"date-parts":[[2024,9,17]],"date-time":"2024-09-17T22:52:14Z","timestamp":1726613534000},"page":"100343","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["A RESPONSE to anti\u2013IL-5 therapy in comorbid patients with chronic rhinosinusitis with nasal polyps and severe asthma: Study protocol"],"prefix":"10.1016","volume":"4","author":[{"given":"Petros","family":"Bakakos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isam","family":"Alobid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jannis","family":"Constantinidis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Hellings","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver","family":"Pfaar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camille","family":"Taill\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Ba\u00f1as-Conejero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konstantina","family":"Kallinikou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Howarth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2678-1373","authenticated-orcid":false,"given":"Florence","family":"Schleich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacig.2024.100343_bib1","doi-asserted-by":"crossref","first-page":"168","DOI":"10.18176\/jiaci.0856","article-title":"Severe asthma and biologics: managing complex patients","volume":"33","author":"Matucci","year":"2023","journal-title":"J Invest Allergol Clin Immunol"},{"key":"10.1016\/j.jacig.2024.100343_bib2","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1111\/all.15301","article-title":"Epidemiology and treatment of patients with chronic rhinosinusitis with nasal polyps in Germany\u2014a claims data study","volume":"77","author":"Starry","year":"2022","journal-title":"Allergy"},{"key":"10.1016\/j.jacig.2024.100343_bib3","doi-asserted-by":"crossref","first-page":"127","DOI":"10.2147\/JAA.S290424","article-title":"Burden of disease in chronic rhinosinusitis with nasal polyps","volume":"14","author":"Bachert","year":"2021","journal-title":"J Asthma Allergy"},{"key":"10.1016\/j.jacig.2024.100343_bib4","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1016\/j.jaip.2018.10.016","article-title":"The Severe Asthma Network in Italy: findings and perspectives","volume":"7","author":"Heffler","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jacig.2024.100343_bib5","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.chest.2021.04.013","article-title":"Eosinophilic and noneosinophilic asthma: an expert consensus framework to characterize phenotypes in a global real-life severe asthma cohort","volume":"160","author":"Heaney","year":"2021","journal-title":"Chest"},{"key":"10.1016\/j.jacig.2024.100343_bib6","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/cea.13841","article-title":"Clinical evaluation of type 2 disease status in a real-world population of difficult to manage asthma using historic electronic healthcare records of blood eosinophil counts","volume":"51","author":"Azim","year":"2021","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jacig.2024.100343_bib7","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1093\/intimm\/dxp102","article-title":"IL-5- and eosinophil-mediated inflammation: from discovery to therapy","volume":"21","author":"Kouro","year":"2009","journal-title":"Int Immunol"},{"key":"10.1016\/j.jacig.2024.100343_bib8","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1002\/alr.22994","article-title":"The roles of eosinophils and interleukin-5 in the pathophysiology of chronic rhinosinusitis with nasal polyps","volume":"12","author":"Gevaert","year":"2022","journal-title":"Int Forum Allergy Rhinol"},{"key":"10.1016\/j.jacig.2024.100343_bib9","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1111\/all.14297","article-title":"Human airway epithelial cells express a functional IL-5 receptor","volume":"75","author":"Barretto","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.jacig.2024.100343_bib10","doi-asserted-by":"crossref","first-page":"392","DOI":"10.4193\/Rhino10.261","article-title":"Mucosal eosinophilia and recurrence of nasal polyps\u2014new classification of chronic rhinosinusitis","volume":"49","author":"Nakayama","year":"2011","journal-title":"Rhinology"},{"key":"10.1016\/j.jacig.2024.100343_bib11","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.jaci.2022.02.029","article-title":"Prognostic factors for polyp recurrence in chronic rhinosinusitis with nasal polyps","volume":"150","author":"Bai","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jacig.2024.100343_bib12","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s13601-020-00332-z","article-title":"Distinct type 2\u2013high inflammation associated molecular signatures of chronic rhinosinusitis with nasal polyps with comorbid asthma","volume":"10","author":"Wang","year":"2020","journal-title":"Clin Transl Allergy"},{"key":"10.1016\/j.jacig.2024.100343_bib13","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/j.jaci.2020.02.002","article-title":"Severe eosinophilic asthma with nasal polyposis: a phenotype for improved sinonasal and asthma outcomes with mepolizumab therapy","volume":"145","author":"Howarth","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jacig.2024.100343_bib14","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1164\/ajrccm.161.6.9906121","article-title":"Segmental bronchial provocation induces nasal inflammation in allergic rhinitis patients","volume":"161","author":"Braunstahl","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jacig.2024.100343_bib15","doi-asserted-by":"crossref","first-page":"3055","DOI":"10.1016\/j.jaip.2023.05.043","article-title":"Patients with asthma only sensitized to Staphylococcus aureus enterotoxins have more exacerbations, airflow limitation, and higher levels of sputum IL-5 and IgE","volume":"11","author":"Schleich","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jacig.2024.100343_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2020.105947","article-title":"Chronic rhinosinusitis with nasal polyps impact in severe asthma patients: evidences from the Severe Asthma Network Italy (SANI) registry","volume":"166","author":"Canonica","year":"2020","journal-title":"Respir Med"},{"key":"10.1016\/j.jacig.2024.100343_bib17","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1183\/13993003.00779-2015","article-title":"Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort","volume":"46","author":"Shaw","year":"2015","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jacig.2024.100343_bib18","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1016\/j.jaip.2022.05.042","article-title":"REALITI-A study: real-world oral corticosteroid-sparing effect of mepolizumab in severe asthma","volume":"10","author":"Pilette","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jacig.2024.100343_bib19","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1016\/j.rmed.2014.10.007","article-title":"Heterogeneity of phenotypes in severe asthmatics. The Belgian Severe Asthma Registry (BSAR)","volume":"108","author":"Schleich","year":"2014","journal-title":"Respir Med"},{"issue":"suppl S29","key":"10.1016\/j.jacig.2024.100343_bib20","first-page":"1","article-title":"European position paper on rhinosinusitis and nasal polyps, 2020","volume":"58","author":"Fokkens","year":"2020","journal-title":"Rhinology"},{"key":"10.1016\/j.jacig.2024.100343_bib21","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.jaci.2017.05.044","article-title":"Reduced need for surgery in severe nasal polyposis with mepolizumab: randomized trial","volume":"140","author":"Bachert","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jacig.2024.100343_bib22","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1164\/rccm.201602-0419OC","article-title":"Inflammatory and comorbid features of patients with severe asthma and frequent exacerbations","volume":"195","author":"Denlinger","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jacig.2024.100343_bib23","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.jaip.2016.12.027","article-title":"Clinical characteristics of patients with chronic rhinosinusitis with nasal polyps, asthma, and aspirin-exacerbated respiratory disease","volume":"5","author":"Stevens","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jacig.2024.100343_bib24","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.jaip.2020.09.063","article-title":"Chronic Rhinosinusitis with nasal polyps and asthma","volume":"9","author":"Laidlaw","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jacig.2024.100343_bib25","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1002\/alr.21674","article-title":"Prevalence of confirmed asthma varies in chronic rhinosinusitis subtypes","volume":"6","author":"Promsopa","year":"2016","journal-title":"Int Forum Allergy Rhinol"},{"key":"10.1016\/j.jacig.2024.100343_bib26","doi-asserted-by":"crossref","first-page":"145","DOI":"10.2500\/ajra.2009.23.3284","article-title":"Relationships between severity of chronic rhinosinusitis and nasal polyposis, asthma, and atopy","volume":"23","author":"Pearlman","year":"2009","journal-title":"Am J Rhinol Allergy"},{"key":"10.1016\/j.jacig.2024.100343_bib27","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1111\/all.15056","article-title":"From DREAM to REALITI-A and beyond: mepolizumab for the treatment of eosinophil-driven diseases","volume":"77","author":"Pavord","year":"2022","journal-title":"Allergy"},{"key":"10.1016\/j.jacig.2024.100343_bib29","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1007\/s40265-021-01597-9","article-title":"Real world effectiveness and safety of mepolizumab in a multicentric Spanish cohort of asthma patients stratified by eosinophils: the REDES study","volume":"81","author":"Domingo Ribas","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.jacig.2024.100343_bib30","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02345-2019","article-title":"Mepolizumab in a population with severe eosinophilic asthma and corticosteroid dependence: results from a French early access programme","volume":"55","author":"Taill\u00e9","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jacig.2024.100343_bib31","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/cea.13601","article-title":"Real-word experience with mepolizumab: does it deliver what it has promised?","volume":"50","author":"Schleich","year":"2020","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jacig.2024.100343_bib32","doi-asserted-by":"crossref","first-page":"1902420","DOI":"10.1183\/13993003.02420-2019","article-title":"Mepolizumab effectiveness and identification of super-responders in severe asthma","volume":"55","author":"Harvey","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jacig.2024.100343_bib33","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1080\/02770903.2022.2036754","article-title":"Long-term retention rate of mepolizumab treatment in severe asthma: a 36-months real-life experience","volume":"60","author":"Matucci","year":"2023","journal-title":"J Asthma"},{"key":"10.1016\/j.jacig.2024.100343_bib34","doi-asserted-by":"crossref","first-page":"2848","DOI":"10.1111\/all.15382","article-title":"RELIght: a two-year REal-LIfe study of mepolizumab in patients with severe eosinophilic asTHma in Greece: evaluating the multiple components of response","volume":"77","author":"Kallieri","year":"2022","journal-title":"Allergy"},{"key":"10.1016\/j.jacig.2024.100343_bib35","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S2213-2600(21)00097-7","article-title":"Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"9","author":"Han","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jacig.2024.100343_bib36","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/alr.22741","article-title":"International consensus statement on allergy and rhinology: rhinosinusitis 2021","volume":"11","author":"Orlandi","year":"2021","journal-title":"Int Forum Allergy Rhinol"},{"key":"10.1016\/j.jacig.2024.100343_bib37","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1111\/all.13875","article-title":"EUFOREA consensus on biologics for CRSwNP with or without asthma","volume":"74","author":"Fokkens","year":"2019","journal-title":"Allergy"},{"key":"10.1016\/j.jacig.2024.100343_bib38","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1007\/s00106-023-01273-2","volume":"71","author":"Pfaar","year":"2023","journal-title":"HNO"},{"key":"10.1016\/j.jacig.2024.100343_bib39","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacig.2024.100343_bib40","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S2213-2600(17)30125-X","article-title":"Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial","volume":"5","author":"Chupp","year":"2017","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jacig.2024.100343_bib41","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1016\/j.jaci.2021.10.040","article-title":"Mepolizumab for chronic rhinosinusitis with nasal polyps: treatment efficacy by comorbidity and blood eosinophil count","volume":"149","author":"Bachert","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jacig.2024.100343_bib42","article-title":"The impact of comorbid nasal polyps on real-world mepolizumab effectiveness in patients with severe asthma: results from the REALITI-A study (abstract)","volume":"205","author":"Liu","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"issue":"suppl\u00a066","key":"10.1016\/j.jacig.2024.100343_bib43","first-page":"2028","article-title":"REDES study: mepolizumab is effective in patients with severe eosinophilic asthma and comorbid NP","volume":"60","author":"Arismendi","year":"2022","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jacig.2024.100343_bib44","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1016\/j.chest.2023.01.037","article-title":"Sputum type 2 markers could predict remission in severe asthma treated with anti\u2013IL-5","volume":"163","author":"Moermans","year":"2023","journal-title":"Chest"},{"issue":"6 pt 1","key":"10.1016\/j.jacig.2024.100343_bib45","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0091-6749(97)80019-X","article-title":"IL-5 synthesis is upregulated in human nasal polyp tissue","volume":"99","author":"Bachert","year":"1997","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jacig.2024.100343_bib46","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0058388","article-title":"Sputum IgE and cytokines in asthma: relationship with sputum cellular profile","volume":"8","author":"Manise","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jacig.2024.100343_bib47","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1016\/j.jaip.2023.05.011","article-title":"The unified airway hypothesis: evidence from specific intervention with anti\u2013IL-5 biologic therapy","volume":"11","author":"Bachert","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jacig.2024.100343_bib48","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.jaci.2022.08.021","article-title":"Updates on immune mechanisms in aspirin-exacerbated respiratory disease","volume":"151","author":"Laidlaw","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jacig.2024.100343_bib49","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0151-2019","article-title":"Short-course systemic corticosteroids in asthma: striking the balance between efficacy and safety","volume":"29","author":"Price","year":"2020","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.jacig.2024.100343_bib50","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1007\/s11882-014-0440-x","article-title":"Management of chronic rhinosinusitis in asthma patients: is there still a debate?","volume":"14","author":"Lehrer","year":"2014","journal-title":"Curr Allergy Asthma Rep"},{"key":"10.1016\/j.jacig.2024.100343_bib51","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/j.1398-9995.2005.00725.x","article-title":"Nasal polyposis and its impact on quality of life: comparison between the effects of medical and surgical treatments","volume":"60","author":"Alobid","year":"2005","journal-title":"Allergy"},{"key":"10.1016\/j.jacig.2024.100343_bib52","doi-asserted-by":"crossref","first-page":"519","DOI":"10.4193\/Rhino10.295","article-title":"Persistent asthma has an accumulative impact on the loss of smell in patients with nasal polyposis","volume":"49","author":"Alobid","year":"2011","journal-title":"Rhinology"},{"key":"10.1016\/j.jacig.2024.100343_bib53","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1111\/j.1398-9995.2008.01870.x","article-title":"Functional endoscopic sinus surgery improved asthma symptoms as well as PEFR and olfaction in patients with nasal polyposis","volume":"64","author":"Ehnhage","year":"2009","journal-title":"Allergy"},{"key":"10.1016\/j.jacig.2024.100343_bib54","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1002\/alr.21994","article-title":"Role of tissue eosinophils in chronic rhinosinusitis\u2013associated olfactory loss","volume":"7","author":"Hauser","year":"2017","journal-title":"Int Forum Allergy Rhinol"},{"key":"10.1016\/j.jacig.2024.100343_bib55","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/intimm\/dxy061","article-title":"Eosinophil-derived neurotoxin enhances airway remodeling in eosinophilic chronic rhinosinusitis and correlates with disease severity","volume":"31","author":"Tsuda","year":"2019","journal-title":"Int Immunol"},{"key":"10.1016\/j.jacig.2024.100343_bib56","first-page":"343","article-title":"The GALEN rhinosinusitis cohort: chronic rhinosinusitis with nasal polyps affects health-related quality of life","volume":"57","author":"Khan","year":"2019","journal-title":"Rhinology"},{"key":"10.1016\/j.jacig.2024.100343_bib57","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1150162","article-title":"Remission outcomes in severe eosinophilic asthma with mepolizumab therapy: analysis of the REDES study","volume":"14","author":"Pavord","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.jacig.2024.100343_bib58","doi-asserted-by":"crossref","first-page":"7056","DOI":"10.3390\/jcm11237056","article-title":"Nasal symptoms in asthmatic patients under treatment with anti\u2013IL-5 monoclonal antibodies. A real-life cohort study","volume":"11","author":"Maza-Solano","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.jacig.2024.100343_bib59","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.3390\/jpm12081304","article-title":"Mepolizumab improves outcomes of chronic rhinosinusitis with nasal polyps in severe asthmatic patients: a multicentric real-life study","volume":"12","author":"Gallo","year":"2022","journal-title":"J Pers Med"},{"key":"10.1016\/j.jacig.2024.100343_bib60","doi-asserted-by":"crossref","first-page":"485","DOI":"10.3390\/biomedicines11020485","article-title":"Real-life effectiveness of mepolizumab in refractory chronic rhinosinusitis with nasal polyps","volume":"11","author":"Dom\u00ednguez-Sosa","year":"2023","journal-title":"Biomedicines"}],"container-title":["Journal of Allergy and Clinical Immunology: Global"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772829324001395?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772829324001395?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,2]],"date-time":"2025-02-02T17:59:24Z","timestamp":1738519164000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772829324001395"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":59,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S2772829324001395"],"URL":"https:\/\/doi.org\/10.1016\/j.jacig.2024.100343","relation":{},"ISSN":["2772-8293"],"issn-type":[{"type":"print","value":"2772-8293"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A RESPONSE to anti\u2013IL-5 therapy in comorbid patients with chronic rhinosinusitis with nasal polyps and severe asthma: Study protocol","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology: Global","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacig.2024.100343","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}],"article-number":"100343"}}